Download App

Log in to access Online Inquiry
Company Overview More
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company’s lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam’s base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.
CEO: Francois M.D., Ph.D., Cedric
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

APLS Apellis Pharmaceuticals

44.420-0.390-0.87%
Close 05/23 18:03 ET
44.390-0.03-0.07%
Post Mkt Price 05/23 16:43 ET
High
45.530
Open
45.140
Turnover
27.84M
Low
43.770
Pre Close
44.810
Volume
623.65K
Market Cap
4.73B
P/E(TTM)
Loss
52wk High
73.000
Shares
106.52M
P/E(Static)
Loss
52wk Low
27.500
Float Cap
3.62B
Bid/Ask %
-100.00%
Historical High
73.000
Shs Float
81.57M
Volume Ratio
0.50
Historical Low
11.450
Dividend TTM
--
Div Yield TTM
650
P/B
10.24
Dividend LFY
--
Div Yield LFY
1463.30%
Turnover Ratio
0.77%
Amplitude
3.93%
Avg Price
44.641
Lot Size
1
Float Cap
3.62B
Bid/Ask %
-100.00%
Historical High
73.000
Shs Float
81.57M
Volume Ratio
0.50
Historical Low
11.450
Dividend TTM
--
P/B
10.24
Dividend LFY
--
Turnover Ratio
0.77%
Amplitude
3.93%
Avg Price
44.641
Lot Size
1
Price Forecast

No Data

News

Comment